Risk benefit analysis to evaluate risk of thromboembolic events after mRNA COVID-19 vaccination and COVID-19.
Journal
NPJ vaccines
ISSN: 2059-0105
Titre abrégé: NPJ Vaccines
Pays: England
ID NLM: 101699863
Informations de publication
Date de publication:
13 Sep 2024
13 Sep 2024
Historique:
received:
06
05
2024
accepted:
29
08
2024
medline:
14
9
2024
pubmed:
14
9
2024
entrez:
13
9
2024
Statut:
epublish
Résumé
We compared the risks and benefits of COVID-19 vaccines using a causal pathway analysis to weigh up possible risk factors of thromboembolic events post-vaccination. The self-controlled case series (SCCS) method examined the association between thromboembolic events and vaccination while a case-control study assessed the association between thromboembolic events and COVID-19, addressing under-reported infection data issues. The net vaccine effect was estimated using results from SCCS and case-control studies. We used electronic health record data from Corewell Health (16,640 subjects in SCCS and 106,143 in case-control). We found increased risks of thromboembolic events post-vaccination (incidence rate ratio: 1.19, 95% CI: [1.08, 1.31] after the first dose; 1.22, 95% CI: [1.11, 1.34] after the second dose). Vaccination attenuated infection-associated thromboembolic risks (odds ratio: 4.65, 95% CI: [4.18, 5.17] in unvaccinated vs 2.77, 95% CI: [2.40, 3.24] in vaccinated). After accounting for vaccine efficacy and protection against infection-associated thromboembolic events, vaccination decreases thromboembolic event risk, especially during high infection rate periods.
Identifiants
pubmed: 39271677
doi: 10.1038/s41541-024-00960-7
pii: 10.1038/s41541-024-00960-7
doi:
Types de publication
Journal Article
Langues
eng
Pagination
166Subventions
Organisme : Foundation for the National Institutes of Health (Foundation for the National Institutes of Health, Inc.)
ID : R01AI158543
Informations de copyright
© 2024. The Author(s).
Références
Centers for Disease Control and Prevention. COVID Data Tracker. Atlanta, GA: U.S. Department of Health and Human Services, CDC; https://covid.cdc.gov/covid-data-tracker (2023).
Avinash, M. & Vineeta, O. Thromboembolism after COVID-19 vaccination: a systematic review of such events in 286 patients. Ann. Vasc. Surg. 84, 12–20 (2022).
doi: 10.1016/j.avsg.2022.05.001
Fan, B. E. et al. COVID-19 mRNA vaccine-associated cerebral venous thrombosis: rare adverse event or coincidence? Am. J. Hematol. 98, E4–E7 (2023).
Leonor, D. et al. Cerebral venous thrombosis after BNT162b2 mRNA SARS-CoV-2 vaccine. J. Stroke Cerebrovasc. Dis. 30, 105906 (2022).
Elizabeth, A. A., Rohan, K., Mirnal, C. & Ulka, S. Three cases of acute venous thromboembolism in females after vaccination for coronavirus disease 2019. J. Vasc. Surg. Venous Lymphat. Disord. 10, 14–17 (2021).
Giuseppe, C., Ilaria, N., Marco, R., Salvatore, B., & Alberto, T. Deep vein thrombosis (DVT) occurring shortly after the second dose of mRNA SARS-CoV-2 vaccine. Intern. Emerg. Med. 16, 803–804 (2021).
Zaitun, Z., Nur, A. S. & Abdul, R. I. G. Cerebral venous sinus thrombosis 2 weeks after the first dose of mRNA SARS-CoV-2 vaccine. Acta Neurochir. 163, 2359–2362 (2021).
doi: 10.1007/s00701-021-04860-w
Julia, H. et al. Risk of thrombocytopenia and thromboembolism after COVID-19 vaccination and SARS-CoV-2 positive testing: self-controlled case series study. BMJ. 374, n1931 (2021).
Maxime, T., Masud, H., John, R. G., Sierra, L., & Paul, J. H. Cerebral venous thrombosis and portal vein thrombosis: a retrospective cohort study of 537,913 COVID-19 cases. EClinicalMedicine. 39, 101061 (2021).
Farah, Y. et al. Adverse events following COVID‐19 mRNA vaccines: a systematic review of cardiovascular complication, thrombosis, and thrombocytopenia. Immun. Inflamm. Dis. 11, e807 (2023).
Frederick, K. H. et al. Thromboembolic risk in hospitalized and nonhospitalized COVID-19 patients: a self-controlled case series analysis of a nationwide cohort. Mayo Clin. Proc. 96, 2587–2597 (2021).
Xiaoming, X., Jianhua, C., & Qinglei, G. Prevalence and risk factors of thrombotic events on patients with COVID-19: a systematic review and meta‐analysis. Thromb. J. 19, 32 (2021).
Sam, S., Yu, H., & Stavros, K. Venous thromboembolism in COVID-19. Thromb. Haemost. 120, 1642–1653 (2020).
Ioannis, K., Osvaldo, F., Paddy, F., Krister, L., & Anne-Marie, F. C. Risk of acute myocardial infarction and ischaemic stroke following COVID-19 in Sweden: a self-controlled case series and matched cohort study. Lancet. 398, 599–607 (2021).
Mahmoud, B. M. et al. Thromboembolism risk of COVID-19 is high and associated with a higher risk of mortality: a systematic review and meta-analysis. EClinicalMedicine. 29, 100639 (2020).
Ahuja, N. et al. Venous thromboembolism in patients with COVID-19 infection: risk factors, prevention, and management. Semin. Vasc. Surg. 34, 101–116 (2021).
Yu, Y. et al. Incidence and risk factors of deep vein thrombosis in hospitalized COVID-19 patients. Clin. Appl. Thromb. Hemost. 26, 1076029620953217 (2020).
Klok, F. A. et al. Confirmation of the high cumulative incidence of thrombotic complications in critically ill ICU patients with COVID-19: an updated analysis. Thromb. Res. 191, 148–150 (2020).
doi: 10.1016/j.thromres.2020.04.041
pubmed: 32381264
pmcid: 7192101
Simpson, C. R. et al. First-dose ChAdOx1 and BNT162b2 COVID-19 vaccines and thrombocytopenic, thromboembolic and hemorrhagic events in Scotland. Nat. Med. 29, 1290–1297 (2021).
doi: 10.1038/s41591-021-01408-4
Marie, J. J. et al. Myocardial infarction, stroke, and pulmonary embolism after BNT162b2 mRNA COVID-19 vaccine in people aged 75 years or older. JAMA 327, 80–82 (2022).
doi: 10.1001/jama.2021.21699
Jacob, D. B. et al. Analysis of thromboembolic and thrombocytopenic events after the AZD1222, BNT162b2, and MRNA-1273 COVID-19 vaccines in 3 Nordic Countries. JAMA Netw. Open. 5, e2217375 (2022).
Chui, C. S. L. et al. Thromboembolic events and hemorrhagic stroke after mRNA (BNT162b2) and inactivated (CoronaVac) covid-19 vaccination: a self-controlled case series study. EClinicalMedicine 50, 101504 (2020).
doi: 10.1016/j.eclinm.2022.101504
Whitaker, H. J., Farrington, C. P., Spiessens, B., & Musonda P. Tutorial in biostatistics: the self-controlled case series method. Stat. Med. 25, 1768–1797 (2006).
Gareth, J. G. et al. Collider bias undermines our understanding of COVID-19 disease risk and severity. Nat. Commun. 11, 5749 (2020).
Bu, F. et al. Bayesian safety surveillance with adaptive bias correction. Stat. Med. 43(2), 395–418 (2023).
doi: 10.1002/sim.9968
pubmed: 38010062
Knudson, M. M., Ikossi, D. G., Khaw, L., Morabito, D. & Speetzen, L. S. Thromboembolism after trauma: an analysis of 1602 episodes from the American College of Surgeons National Trauma Data Bank. Ann. Surg. 240, 490–498 (2004).
doi: 10.1097/01.sla.0000137138.40116.6c
pubmed: 15319720
pmcid: 1356439
Van, S. K. J., Rosendaal, F. R., & Doggen, C. J. Minor injuries as a risk factor for venous thrombosis. Arch. Intern. Med. 168, 21–26 (2008).
Charlson, M. E., Pompei, P., Ales, K. L. & MacKenzie, C. R. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J. Chronic Dis. 40, 373–383 (1987).
doi: 10.1016/0021-9681(87)90171-8
pubmed: 3558716
Gasparini, A. An R package for computing comorbidity scores. J. Open Source Softw. 3, 648 (2018).
doi: 10.21105/joss.00648
Fleming-Dutra, K. E. et al. Association of prior BNT162b2 COVID-19 vaccination with symptomatic SARS-CoV-2 infection in children and adolescents during omicron predominance. JAMA 327, 2210–2219 (2022).
Katherine, E. F. et al. Preliminary estimates of effectiveness of monovalent mRNA vaccines in preventing symptomatic SARS-CoV-2 infection among children aged 3–5 years—increasing community access to testing program, United States, July 2022–February 2023. MMWR Morb. Mortal. Wkly. Rep. 72, 177–182 (2023).
doi: 10.15585/mmwr.mm7207a3
Kelly, M. H. et al. Effectiveness of coronavirus disease 2019 (COVID-19) vaccination against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection among residents of US nursing homes before and during the delta variant predominance. Clin. Infect. Dis. 75, S147–S154 (2022).
Silverstein, M. D., Heit, J. A., Mohr, D. N., Petterson, T. M., O’Fallon, W. M., & Melton. L. J. Trends in the incidence of deep vein thrombosis and pulmonary embolism: a 25-year population-based study. Arch. Intern. Med. 158, 585–593 (1999).
Chen, S. et al. Efficacy of COVID-19 vaccines in patients taking immunosuppressants. Ann. Rheum. Dis. 81, 875–880 (2022).
doi: 10.1136/annrheumdis-2021-222045
Malcolm, R. et al. Comparative effectiveness of coronavirus disease 2019 (COVID-19) vaccines against the delta variant. Clin. Infect. Dis. 75, e623–e629 (2022).
Malcolm, R. et al. COVID-19 vaccine effectiveness against omicron (B.1.1.529) variant infection and hospitalisation in patients taking immunosuppressive medications: a retrospective cohort study. Lancet Rheumatol. 4, e775–e784 (2022).
Martian, P. et al. Risk of myocarditis after sequential doses of COVID-19 vaccine and SARS-CoV-2 infection by age and sex. Circulation. 146, 743–754 (2022).
Huiting, L. et al. Acute kidney injury after COVID-19 vaccines: a real-world study. Ren. Fail. 44, 958–965 (2022).
Fabrizi, F. et al. COVID-19 and acute kidney injury: a systematic review and meta-analysis. Pathogens 9, 1052 (2020).